PatientsVille.com Logo


Pneumonia Medical Research Studies

Up-to-date List of Pneumonia Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Pneumonia Medical Research Studies

Rank Status Study
1 Unknown  Operational Research Management for Children With Severe Pneumonia
Condition: Pneumonia
Interventions: Other: Amoxycilline, Cephradine followed by follow up on day 3;   Other: Injectable ampicillin followed by urgent referral
Outcome Measures: Proportion of Severe Pneumonia cases approapriately treated as per the Modified IMCI guideline;   Proportion of severe Pneumonia cases complied appropriately with followup advice given by the health care providers;   Proportion of childhood Pneumonia cases treated by trained service provider
2 Not yet recruiting Safety, Tolerability, and Efficacy Study of Prophylactic Streptococcus Pneumoniae Vaccine Following Challenge With S. Pneumoniae
Conditions: Pneumococcal Infections;   Streptococcus Pneumoniae;   Pneumonia, Pneumococcal
Interventions: Biological: GEN-004 with Aluminum Hydroxide Adjuvant;   Biological: Placebo
Outcome Measures: Efficacy of GEN-003 as measured by reduction in nasopharyngeal colonization;   Evaluation of the safety and tolerability of GEN-004 with aluminum hydroxide as measured by frequency and severity of Adverse Events;   Evaluation of the duration of S. Pneumoniae colonization through 14 days after inoculation;   Evaluation of the immunogenicity of GEN-004 with aluminum hydroxide, as measured by TH17 (IL-17) and IgG responses to the antigens.
3 Unknown  Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children
Conditions: Viral Pneumonia;   Bacterial Pneumonia
Outcome Measures: TREM-1 level in the BAL fluid of patients with pure viral Pneumonia in comparison to patients with viral with co-existing bacterial Pneumonia;   TREM-1 level in the BAL fluid of patients with pure bacterial Pneumonia and no Pneumonia;   TREM-1 level in the serum of all 4 groups;   Length of ventilator support, length of ICU and hospital stay
4 Unknown  Microbiology and Clinical Outcome of Pneumonia
Condition: Pneumonia
Outcome Measure: Success/favorable clinical response after treatment for Pneumonia
5 Unknown  Zinc as Adjunct to Treatment of Pneumonia
Condition: Pneumonia
Intervention: Dietary Supplement: Zinc sulphate
Outcome Measures: Time (hours) to resolution of clinical signs of Pneumonia;   Time (hours) to resolution of clinical signs of Pneumonia by type of associated pathiogens ( bacterial/viral)
6 Recruiting Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine
Condition: Community Acquired Pneumonia
Interventions: Behavioral: BPS;   Behavioral: Guideline
Outcome Measures: Use of Antibiotics in Each Group;   Treatment Failure in Each Group
7 Not yet recruiting The Effectiveness of Co-packaging With Zinc to Improve Treatment of Diarrhea and Pneumonia in Guatemala
Conditions: Diarrhea.;   Pneumonia.
Intervention: Behavioral: Co-packaging and counseling messages
Outcome Measures: Percentage of caregivers who administer zinc to child for at least 8 days.;   Percentage of caregivers who report giving zinc to child for at least 8 days.;   Improved Provision of Care for Treatment of Diarrhea and Pneumonia
8 Unknown  Prevention of Post-operative Pneumonia (POPP)
Conditions: Post-operative Pneumonia;   Lung Cancer;   Esophageal Cancer
Intervention: Procedure: Intensive Brushing Regimen
Outcome Measures: Incidence of postoperative Pneumonia in the two groups: lung cancer resection patients and esophageal resection patients;   Compliance with preoperative brushing and mouthwash protocol
9 Recruiting Surveillance of Hospitalised Pneumonia and Bacterial Meningitis in Tône District, Togo, 2010-2013
Conditions: Pneumonia, Bacterial;   Pneumonia, Viral;   Meningitis, Bacterial
Outcome Measures: Incidence of pneumococcal Pneumonia requiring hospitalisation, confirmed by blood culture or PCR analysis of blood;   Incidence of pneumococcal meningitis, confirmed by culture or PCR on cerebro-spinal fluid;   Incidence of radiologically confirmed Pneumonia requiring hospitalisation;   Incidence of suspected Pneumonia requiring hospitalisation with elevated C-reactive protein serum concentration (<40mg/l);   Incidence of suspected Pneumonia requiring hospitalisation with reduced oxygen saturation (<90%);   Incidence of Pneumonia of other bacterial or viral etiology requiring hospitalisation;   Incidence of acute meningitis of other bacterial etiology
10 Unknown  Usefulness of Microbiological Tests in Community-Acquired Pneumonia
Condition: Community-Acquired Pneumonia
Intervention: Procedure: empirical versus microbiological guided treatment
Outcome Measures: Clinical and economic consequences obtained with the antibiotic selection in basis to early mcrobiological results;   Importance of polimicrobial etiology in community-acquired Pneumonia;   Practice usefulness of urinary antigen detection tests in Pneumonia
11 Unknown  Flu Vaccine Against Childhood Pneumonia, Bangladesh
Conditions: Pneumonia;   Laboratory Confirmed Influenza
Intervention: Biological: Trivalent inactivated influenza vaccine
Outcome Measures: Clinical Pneumonia;   Laboratory confirmed influenza infection;   Indirect effects;   Epidemiological and clinical characteristics of influenza infection;   Effect on non-influenza viral and bacterial invasive disease;   Immunogenicity;   Adverse events associated with the vaccine
12 Unknown  Impact of a Multidimensional Intervention in Elderly Patients With Pneumonia
Conditions: Community Acquired Pneumonia;   Healthcare-Associated Pneumonia
Intervention: Other: Multidimensional intervention
Outcome Measures: Healthcare resources utilization (readmissions and consultations to hospital and emergency department).;   Functional status;   Institutionalization;   Survival
13 Not yet recruiting Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia
Condition: Nosocomial Pneumonia
Interventions: Drug: ceftolozane/tazobactam;   Drug: Meropenem
Outcome Measures: All Cause Mortality;   Clinical response rates of ceftolozane/tazobactam versus meropenem in adult subjects with VNP.;   Clinical response rates at the Late Follow-up (LFU) visit for ceftolozane/tazobactam versus meropenem in adult subjects with VNP.;   Per-pathogen microbiological response rates of ceftolozane/tazobactam versus meropenem at TOC.;   Microbiological response rates of ceftolozane/tazobactam versus meropenem at EOT;   Clinical response rates at the TOC visit (ceftolozane/tazobactam versus meropenem) in the subset of subjects who had P. aeruginosa from the baseline lower respiratory tract culture;   Day 14 all-cause mortality rates of subjects in the ceftolozane/tazobactam versus meropenem arms;   Safety will be evaluated in the safety population by presenting summaries of deaths, AEs, laboratory evaluations, vital signs and physical exam in the 2 treatment groups;   Pharmacokinetic parameters, such as maximum concentration achieved (Cmax), total exposure during one dosing interval (AUC0-τ), steady-state volume of distribution (Vss) and Clearance (CLss);   Day 28 all-cause mortality rates of subjects in the ceftolozane/tazobactam versus meropenem arms in the Microbiological Intent-to-Treat (mITT) population;   Clinical response rates at the TOC visit (ceftolozane/tazobactam versus meropenem) in the subset of subjects who had Enterobacteriaceae isolated from the baseline lower respiratory tract culture;   Per-pathogen clinical response at TOC by baseline minimum inhibitory concentration (MIC) and Kirby-Bauer zone diameter for ceftolozane/tazobactam versus meropenem
14 Unknown  Ventilator Associated Pneumonia in Taper Guard Versus Normal Tube in ICU Patients
Condition: Ventilator Associated Pneumonia
Interventions: Device: Taper Guard Endotracheal Tube;   Other: Conventional endotracheal tube
Outcome Measures: incidence of ventilator associated Pneumonia(VAP);   Number of days on the ventilator by the time patient is discharged from ICU or hospital or at time of death;   The total number of days spent in the intensive care unit by the time of discharge from hospital or death;   The number of days spent in the hospital by the time of discharge or death;   number of deaths in each arm
15 Recruiting A Randomized Controlled Trial of Lung Ultrasound Compared to Chest X-ray for Diagnosing Pneumonia in the Emergency Department
Condition: Pneumonia
Interventions: Other: Lung Ultrasound;   Radiation: Chest X-Ray
Outcome Measures: Overall reduction of CXR needed to diagnose Pneumonia;   Comparison of unscheduled healthcare visits after the index Emergency Department visit between those subjects who undergo CXR first and those who undergo LUS first.;   Evaluation of the rate of antibiotic use between the two groups.;   Comparison of the admission rates.;   Comparison of the length of stay in the Emergency Department between the two groups.
16 Recruiting Effect of Atorvastatin on the Frequency of Ventilator-associated Pneumonia in Patients With Ischemic Stroke
Conditions: Ventilator-associated Pneumonia;   Ischemic Stroke
Interventions: Drug: Atorvastatin;   Drug: Placebo
Outcome Measures: Cumulative frequency of ventilator-associated Pneumonia;   Mortality;   Ventilation free days;   Antibiotic free days;   Whether the bacteria of multidrug-resistance can be isolated from the sputum culture;   Adverse effects
17 Recruiting Duration of Antibiotic Therapy in Community - Acquired Pneumonia
Conditions: Pneumonia;   BronchoPneumonia;   PleuroPneumonia;   Pneumonia, Bacterial;   Pneumonia, Viral
Intervention: Other: Discontinuation of antibiotic therapy
Outcome Measures: Composite outcome including adverse events;   Composite outcome of other adverse events;   Antibiotic exposure;   Adverse effects;   Composite outcome of other adverse events at 90 days;   Length of hospitalization;   Costs
18 Unknown  Effectiveness of H1N1 Influenza Vaccines in Manitoba, Canada
Conditions: Influenza;   Pneumonia
Outcome Measures: Hospitalization with laboratory-confirmed influenza or Pneumonia;   Hospitalization with influenza or Pneumonia
19 Recruiting Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia
Condition: Nosocomial Pneumonia
Interventions: Drug: C Group;   Drug: E Group
Outcome Measures: Extension of the Piperacillin / tazobactam infusion time effect evaluation;   Reducing antibiotic resistance
20 Recruiting Pharmacokinetics of Moxifloxacin in Patients With Pneumonia
Condition: Pneumonia
Outcome Measure: The concentration of Moxifloxacin in blood-plasma

These studies may lead to new treatments and are adding insight into Pneumonia etiology and treatment.

A major focus of Pneumonia research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Pneumonia